Martín Caballero, JuanGarzón, AnaGonzález-Cintado, LeticiaKowalczyk, WioletaJiménez Torres, IgnacioCalderita, GloriaRodríguez, MargaritaGondar, VirgíniaBernal, Juan JoseArdavín, CarlosAndreu Martínez, DavidZürcher, ThomasKobbe, Cayetano von2015-05-132015-05-132012Martin Caballero J, Garzón A, González-Cintado L, Kowalczyk W, Jimenez Torres I, Calderita G et al. Chimeric infectious bursal disease virus-like particles as potent vaccines for eradication of established HPV-16 E7-dependent tumors. PLoS ONE. 2012;7(12):e52976. DOI: 10.1371/journal.pone.00529761932-6203http://hdl.handle.net/10230/23562Cervical cancer is caused by persistent high-risk human papillomavirus (HR-HPV) infection and represents the second most frequent gynecological malignancy in the world. The HPV-16 type accounts for up to 55% of all cervical cancers. The HPV-16 oncoproteins E6 and E7 are necessary for induction and maintenance of malignant transformation and represent tumor-specific antigens for targeted cytotoxic T lymphocyte–mediated immunotherapy. Therapeutic cancer vaccines have become a challenging area of oncology research in recent decades. Among current cancer immunotherapy strategies, virus-like particle (VLP)–based vaccines have emerged as a potent and safe approach. We generated a vaccine (VLP-E7) incorporating a long C-terminal fragment of HPV-16 E7 protein into the infectious bursal disease virus VLP and tested its therapeutic potential in HLA-A2 humanized transgenic mice grafted with TC1/A2 tumor cells. We performed a series of tumor challenge experiments demonstrating a strong immune response against already-formed tumors (complete eradication). Remarkably, therapeutic efficacy was obtained with a single dose without adjuvant and against two injections of tumor cells, indicating a potent and long-lasting immune response.application/pdfeng© 2012 Martin Caballero et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are creditedPapil·lomavirus -- MalaltiesÚter -- Càncerinfo:eu-repo/semantics/articlehttp://dx.doi.org/10.1371/journal.pone.0052976info:eu-repo/semantics/openAccess